Rosai–Dorfman disease with MAP2K1 mutation: therapeutic response to MEK inhibition after failure of conventional therapy Authors: Carolina Barbosa Carvalho do Carmo, Ana Luiza Potiguara de Sousa, Gabriel Henrique de Souza Alves Glória, Isabella Serpa Andrade Borges, Alesso Cervantes Sartorelli, Alexandre Nonino Published: 2026 ABSTRACT AbstractRosai–Dorfman disease (RDD) is a rare histiocytic disorder, usually benign but may follow an aggressive and treatment-refractory course in a subset of patients. Somatic mutations involving the MAPK/ERK pathway, particularly KRAS and MAP2K1, have been increasingly recognized and provide a rationale for targeted therapy. We report the case of a 41-year-old woman with a two-year history of progressive, multisystem RDD presenting with cervical and mediastinal lymphadenopathy and laryngeal involvement, who was refractory to multiple conventional treatments, including corticosteroids, immunosuppressive agents, immunomodulatory drugs, and chemotherapy. Next-generation sequencing identified a pathogenic MAP2K1 c.607G > A mutation, leading to initiation of MEK inhibition with cobimetinib. The patient achieved complete clinical and radiological response, which has been sustained for more than three years after treatment discontinuation. This case highlights the importance of molecular profiling in refractory RDD and supports MEK inhibition as a promising therapeutic strategy in patients with actionable MAPK pathway mutations.Keywords: Rosai-Dorfman disease, Histiocytosis, non-Langerhans-cell, MAP kinase kinase 1, Cobimetinib, precision medicine, molecular targeted therapy Introduction Rosai–Dorfman disease (RDD), also known as sinus histiocytosis with massive lymphadenopathy, is a rare histiocytic proliferative disorder, typically benign and self-limiting. It often presents with bilateral cervical lymphadenopathy, extranodal involvement can occur [1]. Diagnosis is confirmed by biopsy, with hallmark histiocytes showing S100 [2]. The diagnostic workup typically includes cross-sectional imaging to assess nodal and extranodal involvement. Management is heterogeneous ranging from observation to systemic therapy in disseminated disease. Corticosteroids remain the most frequently used first-line treatment, while chemotherapy and immunosuppressive agents have been employed in refractory cases with variable success. Somatic alterations in the MAPK/ERK pathway, most commonly involving KRAS and MAP2K1, are identified in a subset of patients and have generated interest in targeted therapies, particularly MEK inhibitors, although their use remains off-label [3, 4]. We report the case of a patient with RDD harboring a MAP2K1 mutation who exhibited a significant clinical response to cobimetinib after failure of multiple conventional therapies. This case underscores the value of molecular profiling and highlights the potential of MEK inhibition in refractory RDD. Case report A 41-year-old female patient with a previous diagnosis of hypothyroidism, on levothyroxine, presented with 7% weight loss in two months, chest pain, and large joint arthralgia. She developed cervical and mediastinal lymphadenopathy and was diagnosed with Rosai-Dorfman disease (RDD). Sequential lymph node core biopsies at seven months and two years confirmed persistent disease. Histopathology showed diffuse infiltration by large histiocytes, abundant cytoplasm and prominent emperipolesis on hematoxylin and eosin staining, with strong S100 immunoreactivity, confirming RDD. Histopathological findings are shown in Fig. 1. Histopathological findings of the lymph node biopsy. (A) Low-power view showing diffuse histiocytic infiltration of the lymph node (hematoxylin and eosin). (B) High-power view demonstrating large histiocytes with abundant cytoplasm and prominent emperipolesis (hematoxylin and eosin). (C) Immunohistochemistry showing strong S100 positivity in histiocytes, consistent with Rosai–Dorfman disease. Baseline imaging revealed reactive lymph nodes measuring up to 20 mm in cervical levels II and III (cervical CT, Jan/2019), a 3 mm calcified granuloma in the right lower lobe (thoracic CT, Jan/2019), and bilateral cervical, supraclavicular, and mediastinal hypermetabolic lymphadenopathies on positron emission tomography–computed tomography (PET-CT) using 18F-fluorodeoxyglucose (FDG) (Feb/2019). Abdominal imaging showed no significant abnormalities. From the initial diagnosis in 2019 to the initiation of cobimetinib in 2021, the patient experienced progressive multisystem disease despite multiple lines of systemic therapy. Initial treatment consisted of 4-week cycles of prednisone 100 mg/day for five days, combined with 6-mercaptopurine (6-MP) 100 mg/day, vimblastine 6 mg/m2 every 2 weeks and methotrexate 35 mg/week, from October 2019 to January 2020. Despite initial stabilization, the patient developed intolerance to 6-MP, with cutaneous rash, diarrhea and nausea. Subsequently, cyclophosphamide 50 mg/day was introduced in combination with methotrexate 30 mg and vinblastine, but the regimen was discontinued after seven days due to grade 2 hepatotoxicity. In January 2020, prednisone 40 mg/day was restarted, with pulses of 100 mg in April 2020, along with thalidomide 100 mg/day for seven days in July 2020. However, the disease progressed with lymphadenopathies, pharyngeal and laryngeal involvement, as shown in Fig. 2. Bone densitometry (Jan/2020) revealed osteopenia (L1-L4 Z-score = −2.1). Videolaryngoscopy showing laryngeal involvement. In August 2020, lenalidomide 10 mg/day combined with prednisone was introduced, but without clinical response. The patient subsequently received six cycles of 2-chlorodeoxyadenosine (2-CDA), initially at 6 mg/m2 for three days, followed by 5 mg/m2 for five days, between September and December 2020. Partial regression was achieved, but disease progression occurred three months after completion. Pet CT showed cervical, mediastinal, pulmonary and inguinal hypermetabolic lymphadenopathies as shown in Fig. 3. Pet CT showing cervical, mediastinal, pulmonary and inguinal hypermetabolic lymphadenopathies. Given the refractory course, next-generation sequencing (NGS) using the Target One Pan Cancer panel (52 genes) was done and identified a MAP2K1 c.607G > A mutation. Cobimetinib (Cotellic®) was initiated in May 2021 at a dose of 60 mg/day for 20 days. The regimen was interrupted due to a maculopapulopustular skin rash and reintroduced in July 2021 at 20 mg/day, later titrated to 40 mg/day, maintained for five months. The patient completed 12 treatment cycles in June 2022, achieving complete clinical and radiological response. The evolution of cervical lymphadenopathy can be seen in Fig. 4. Clinical aspect from initial presentation to complete resolution of cervical lymphadenopathy. (A) before treatment. (B) during cobimetinib therapy. (C) after treatment completion (complete resolution). Three years after treatment completion (2025), echocardiograms remained stable, and bone densitometry normalized. More than three years after treatment discontinuation, the patient is in good general condition and ambulatory. On physical examination, a 1.5 cm left posterior cervical lymph node was noted, without significant visceromegaly. The serial evolution of blood results from prior to treatment (March and May 2021), to 2,5 months after introducing cobimetinib (August 2021) until 3 years after treatment (August 2025) is summarized in Table 1. Table 1Laboratory evolution of the patient prior from starting treatment with cobimetinib until after treatment completion.Exam date (day/month/year)30/03/202111/05/202102/08/202112/08/2025Haemoglobin (g/dl)11.412.213.813.5Haematocrit (%)34.635.838.638MCV (fl)94.890.493.594RDW (%)13.81513.311.8Total white cells (mm−3)5400720029003250Neutrophils (mm−3)4644662420591918Platelets (x 103/mm)198 k236 k138 k166 kFerritin (ng/ml)97.450.232Ultrasensitive PCR (mg/dl)31.5452.260.710.5Lactate dehydrogenase (U/l)241198225168Reference values: Haemoglobin: 12 g/dl; Hematocrit: 33.0%–47.8%; MCV: 80.0–98.0; RDW: 11.0%–16.0%; Total white cells: 3600–11 000 mm−3; Neutrophils: 1480–7700; Platelets (x103): 130–450; Ferritin: 10.0–291.0 ng/ml; Ultrasensitive PCR: < 5 mg/l; Lactate dehydrogenase: 120–246 U/l. Laboratory evolution of the patient prior from starting treatment with cobimetinib until after treatment completion. Reference values: Haemoglobin: 12 g/dl; Hematocrit: 33.0%–47.8%; MCV: 80.0–98.0; RDW: 11.0%–16.0%; Total white cells: 3600–11 000 mm−3; Neutrophils: 1480–7700; Platelets (x103): 130–450; Ferritin: 10.0–291.0 ng/ml; Ultrasensitive PCR: < 5 mg/l; Lactate dehydrogenase: 120–246 U/l. Discussion Rosai–Dorfman disease (RDD) remains a therapeutic challenge, particularly in patients with multisystem involvement or refractoriness to conventional treatments such as corticosteroids, immunosuppressants, or chemotherapy. In our patient, the lack of response to multiple systemic regimens prompted molecular investigation, which identified a somatic MAP2K1 mutation and provided a biological rationale for targeting the MAPK/ERK pathway. Although MEK inhibitors are used off-label in RDD, accumulating evidence supports their efficacy in histiocytic disorders. Genomic studies have demonstrated MAPK/ERK pathway alterations in up to one third of RDD cases [3]. In a retrospective cohort, patients harboring these mutations showed significantly higher response rates to MEK inhibition, with complete remission achieved in the majority of cases [5]. Clinical benefit has also been reported in mutation-negative patients, suggesting pathway dependence beyond detectable genomic alterations [6]. Similar results have been observed in other histiocytic neoplasms. In Langerhans cell histiocytosis and Erdheim–Chester disease, MEK inhibitors such as trametinib and cobimetinib have demonstrated high response rates, including in patients without BRAF V600E mutations [7–9]. These findings reinforce the central role of MAPK/ERK activation in non-Langerhans histiocytoses. This case highlights the value of precision medicine in RDD, where genomic profiling can reveal actionable targets and guide therapy. The sustained complete response to cobimetinib, maintained beyond treatment discontinuation, supports the incorporation of molecular testing in refractory disease and adds to the growing body of evidence for MEK inhibition as an effective therapeutic strategy in RDD. Acknowledgements The authors would like to thank the clinical staff involved in the care of this patient. Contributor Information Carolina Barbosa Carvalho do Carmo, Universidade Católica de Brasília, QS 07, Lote 01, Águas Claras, DF, 71966-700 Brasília, Brazil. Ana Luiza Potiguara de Sousa, Universidade Católica de Brasília, QS 07, Lote 01, Águas Claras, DF, 71966-700 Brasília, Brazil. Gabriel Henrique de Souza Alves Glória, Universidade Católica de Brasília, QS 07, Lote 01, Águas Claras, DF, 71966-700 Brasília, Brazil. Isabella Serpa Andrade Borges, Universidade Católica de Brasília, QS 07, Lote 01, Águas Claras, DF, 71966-700 Brasília, Brazil. Alesso Cervantes Sartorelli, Laboratório Diagnose, SGAS 915, Conjunto F, Asa Sul, DF, 70390-150 Brasília, Brazil. Alexandre Nonino, Oncolínicas DF, SGAS 915, Conjunto F, Asa Sul, DF, 70390-150 Brasília, Brazil. Author contributions Carolina Barbosa Carvalho do Carmo: manuscript drafting. Ana Potiguara, Gabriel Henrique, Isabella Serpa: literature review, manuscript preparation. Alexandre Nonino: patient management, critical review of the manuscript. Alesso Sartorelli: patient management, critical review of the manuscript. All authors read and approved the final manuscript. Conflicts of interest The authors declare no conflicts of interest. Funding No funding was received for this work. Consent Written informed consent was obtained from the patient for publication of this case report and all accompanying clinical and histopathological images. References